Related Experiment Videos
Do scarce targets or T killers control primary HIV infection?
David Wick1, Steven G Self, Lawrence Corey
1Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, MW-500, 1100 Fairview Avenue N, Seattle, WA 98109-1024, U.S.A. wick@scharp.org
Journal of Theoretical Biology
|January 29, 2002
Summary
Human immunodeficiency virus (HIV) levels dramatically decrease early in infection. Target-cell depletion cannot explain this decline, supporting immune system control of HIV.
Area of Science:
- Virology
- Immunology
- Mathematical Biology
Background:
- Early human immunodeficiency virus (HIV) infection is characterized by a rapid increase in viral load, reaching up to one million virions per milliliter of blood.
- Following this initial viremic outburst, viral levels decrease significantly (by two orders of magnitude) over several weeks, leading to symptom resolution and a quasi-steady state.
Purpose of the Study:
- To investigate the mechanism responsible for the rapid decline in human immunodeficiency virus (HIV) levels early in infection.
- To evaluate the hypothesis that target-cell depletion explains the reduction in viremia.
- To provide evidence supporting alternative theories, such as immune system control.
Main Methods:
- Analysis of observational data from primary HIV disease.
- Application of mathematical modeling to understand viral dynamics.
- Comparison of empirical observations with theoretical explanations for viral load reduction.
Main Results:
- Mathematical analysis and observational data suggest that target-cell scarcity is insufficient to account for the observed two-orders-of-magnitude drop in HIV viremia.
- The rate of viral decline is inconsistent with depletion of the available target cell population alone.
Conclusions:
- Target-cell depletion does not adequately explain the early control of human immunodeficiency virus (HIV) replication.
- The findings indirectly strengthen the hypothesis that immune system responses are the primary driver of the initial reduction in HIV viral load.